List of Alphagan P drug patents
Alphagan P is owned by Allergan.
Alphagan P contains Brimonidine Tartrate.
Alphagan P has a total of 8 drug patents out of which 6 drug patents have expired.
Expired drug patents of Alphagan P are:
- US9295641*PED
- US6562873*PED
- US9687443*PED
- US6627210*PED
- US6673337*PED
- US6641834*PED
Alphagan P was authorised for market use on 16 March, 2001.
Alphagan P is available in solution/drops;ophthalmic dosage forms.
The generics of Alphagan P are possible to be released after 02 March, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9295641 (Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 4 months ago) | |
|
US6562873 (Pediatric) | ALLERGAN | Compositions containing therapeutically active components having enhanced solubility |
Jan, 2022
(1 year, 4 months ago) | |
|
US9687443 (Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 4 months ago) | |
|
US6627210 (Pediatric) | ALLERGAN | Compositions containing α-2-adrenergic agonist components |
Jan, 2022
(1 year, 4 months ago) | |
|
US6673337 (Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 4 months ago) | |
|
US6641834 (Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 4 months ago) | |
| US8858961 | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(2 months from now) | |
|
US8858961 (Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(8 months from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 16 March, 2001
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic